- The future of pain relief: Exploring opioid alternativesIn this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has…BioSpace · 8d ago↗ source
- J&J sees Spravato sales surge as psychedelic competitors loomPsychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.BioSpace · 8d ago↗ source
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsPrediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.